To determine if CD44 targeting could affect tumour growth in vivo, we used the P245 monoclonal antibody against the CD44 cell surface receptor that was earlier shown to inhibit the development of human leukaemia xenografts (Jin et al, 2006). The gene discussed is CD44; the disease is neoplasm.